Data compiled by Redley Lamar · ChainSifter Intelligence
12Suppliers
15Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
31Total relationships
3Distinct source URLs
9High confidence
0.764Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Corbus Pharmaceuticals Holdings, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CSPC
CSPC
90%
We are a party to a license agreement with CSPC pursuant to which we licensed the exclusive rights in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K., and Aust…
CSPC-MEGALITH-BIOPHARMACEUTICAL-CO-LTD
CSPC-MEGALITH-BIOPHARMACEUTICAL-CO-LTD
90%
The Company paid CSPC an upfront payment of $ 7.5 million
JENRIN-DISCOVERY-LLC
JENRIN-DISCOVERY-LLC
90%
On September 20, 2018, we entered into an exclusive license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), which provides us with an exclusive worldwide license to …
THE-REGENTS
THE-REGENTS
90%
The Company paid The Regents a license issue fee of $ 1.5 million
JENRIN
JENRIN
85%
The Company is obligated to pay Jenrin up to $ 18.0 million in additional potential milestone payments
Reciprocal relationship from AZN graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from AZN grap…
Reciprocal relationship from BCYC graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from BCYC g…
GNMSF
Genmab A/S
72%
Reciprocal relationship from GNMSF graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from GNMS…
Reciprocal relationship from GPCR graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from CRBP graph: designed to be an improved next-gen…
NVO
Novo Nordisk A/S
72%
Reciprocal relationship from NVO graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from NVO graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from NVO grap…
Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large…
Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from VKTX g…
Reciprocal relationship from AZN graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a mono…
designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
Reciprocal relationship from BCYC graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from BCYC g…
GNMSF
Genmab A/S
72%
Reciprocal relationship from GNMSF graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a mo…
GNMSF
Genmab A/S
72%
designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
Reciprocal relationship from GPCR graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from CRBP graph: designed to be an improved next-gen…
designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
NVO
Novo Nordisk A/S
72%
designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
NVO
Novo Nordisk A/S
72%
Reciprocal relationship from NVO graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from NVO graph: Reciprocal relationship from CRBP graph: designed to be an improved next-gener…
Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large…
designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cytotoxic payload using a proprietary linker …
Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: designed to be an improved next-gen…
CORPORATE-INFORMATION-CORBUS-PHARMACEUTICALS-INC
CORPORATE-INFORMATION-CORBUS-PHARMACEUTICALS-INC
62%
ter coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and as…
JB-THERAPEUTICS-INC
JB-THERAPEUTICS-INC
62%
ter coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and as…
Corbus Pharmaceuticals Holdings, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CRBP-DEBT-8833
Warrants outstanding: 2873
90%
xbrl warrant detail from xbrl 2025-12-31.
CRBP-DEBT-8834
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2014-12-31.
CRBP-DEBT
Debt stack $12.8M
90%
Market cache reports total debt of $12.8M.
Corbus Pharmaceuticals Holdings, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Corbus Pharmaceuticals Holdings, Inc..
Corbus Pharmaceuticals Holdings, Inc. Ownership
Holder
Name
Confidence
Evidence
CRBP-OWNER-CORMORANT-ASSET-MANAGEMENT-LP
Cormorant Asset Management, LP
90%
13F overlay lists Cormorant Asset Management, LP as top holder; 107 tracked holders.
Corbus Pharmaceuticals Holdings, Inc. Extended Supply Chain Network
